MX2024009967A - Formulacion farmaceutica. - Google Patents
Formulacion farmaceutica.Info
- Publication number
- MX2024009967A MX2024009967A MX2024009967A MX2024009967A MX2024009967A MX 2024009967 A MX2024009967 A MX 2024009967A MX 2024009967 A MX2024009967 A MX 2024009967A MX 2024009967 A MX2024009967 A MX 2024009967A MX 2024009967 A MX2024009967 A MX 2024009967A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical formulation
- amino
- pharmaceutically acceptable
- pyrazi
- decan
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202211009181 | 2022-02-21 | ||
| PCT/IB2023/051532 WO2023156979A1 (en) | 2022-02-21 | 2023-02-20 | Pharmaceutical formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024009967A true MX2024009967A (es) | 2024-08-26 |
Family
ID=85476156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024009967A MX2024009967A (es) | 2022-02-21 | 2023-02-20 | Formulacion farmaceutica. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250161223A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4482471A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025508402A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240150600A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118715005A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023221615A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3251234A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL314206A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024009967A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202342040A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023156979A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119789849A (zh) * | 2022-08-31 | 2025-04-08 | 阿斯利康(瑞典)有限公司 | 药物制剂 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| CN110730678B (zh) | 2017-01-10 | 2022-07-15 | 诺华股份有限公司 | 包含alk抑制剂和shp2抑制剂的药物组合 |
| IL304526B2 (en) | 2018-09-29 | 2025-05-01 | Novartis Ag | Production of compounds and preparations for inhibiting the activity of SHP2 |
| EP3856345A1 (en) | 2018-09-29 | 2021-08-04 | Novartis AG | Process of manufacture of a compound for inhibiting the activity of shp2 |
| EP3923940B1 (en) | 2019-02-12 | 2025-12-03 | Novartis AG | Pharmaceutical combination comprising tno155 and a pd-1 inhibitor |
| CN113382774A (zh) | 2019-02-12 | 2021-09-10 | 诺华股份有限公司 | 包含tno155和krasg12c抑制剂的药物组合 |
| US12343344B2 (en) | 2019-02-12 | 2025-07-01 | Novartis Ag | Pharmaceutical combination comprising TNO155 and ribociclib |
| US20230090389A1 (en) | 2020-02-28 | 2023-03-23 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor |
-
2023
- 2023-02-18 TW TW112105963A patent/TW202342040A/zh unknown
- 2023-02-20 WO PCT/IB2023/051532 patent/WO2023156979A1/en not_active Ceased
- 2023-02-20 KR KR1020247030717A patent/KR20240150600A/ko active Pending
- 2023-02-20 JP JP2024548368A patent/JP2025508402A/ja active Pending
- 2023-02-20 AU AU2023221615A patent/AU2023221615A1/en active Pending
- 2023-02-20 CN CN202380021982.XA patent/CN118715005A/zh active Pending
- 2023-02-20 CA CA3251234A patent/CA3251234A1/en active Pending
- 2023-02-20 MX MX2024009967A patent/MX2024009967A/es unknown
- 2023-02-20 EP EP23708903.2A patent/EP4482471A1/en active Pending
- 2023-02-20 IL IL314206A patent/IL314206A/en unknown
- 2023-02-20 US US18/839,600 patent/US20250161223A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3251234A1 (en) | 2023-08-24 |
| WO2023156979A1 (en) | 2023-08-24 |
| JP2025508402A (ja) | 2025-03-26 |
| US20250161223A1 (en) | 2025-05-22 |
| TW202342040A (zh) | 2023-11-01 |
| IL314206A (en) | 2024-09-01 |
| AU2023221615A1 (en) | 2024-07-25 |
| EP4482471A1 (en) | 2025-01-01 |
| KR20240150600A (ko) | 2024-10-15 |
| CN118715005A (zh) | 2024-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2156028T3 (es) | Composiciones que contienen tetrahidrolipstatina | |
| WO1997049373A3 (en) | Treatment and prevention of hiv infection by administration of derivatives of human chorionic gonadotropin | |
| FI3986561T3 (fi) | Pyrido[2,3-d]pyrimidiinijohdannaisia ihmisen immuunikatoviruksen replikaation estäjinä | |
| MXPA03010402A (es) | Derivados de 4-amino-5-fenil-7-ciclobutil-pirrolo (2,3-d) pirimidina. | |
| WO2008019996A3 (en) | Formulations of flibanserin and method for manufacturing the same | |
| AU6522090A (en) | Bicyclic pyrimidine derivative, method of producing the same, and pharmaceutical preparation containing the same as active ingredient | |
| GB9007052D0 (en) | Pharmaceutical formulations | |
| EP0375329A3 (en) | Antiviral pyrimidine and purine compounds, process for their preparation and pharmaceutical compositions containing them | |
| AU3951489A (en) | Pharmaceutical formulation for the treatment of diabetes mellitus | |
| ATE329581T1 (de) | Pharmazeutische formulierung, die n-((1-n-butyl-4-piperidinyl)menthyl)-3,4-dihydr -2h-(1, 3)oxazino(3,2-a)indol-10-carboxamid oder ein entsprechendes salz hiervon enthält, sowie deren herstellungsprozess, welcher trockengranulierung beinhaltet | |
| AU1412088A (en) | Therapeutic nucleosides | |
| FI945313A0 (fi) | Parannetun biokäytettävyyden omaavat tabletit, jotka sisältävät dikloorimetyleenifosfonihappoa vaikuttavana aineena | |
| CA2490335A1 (en) | Pharmaceutical composition as solid dosage form and method for manufacturing thereof | |
| CA3242845A1 (en) | SKINCARE FORMULATIONS AND METHODS | |
| CA2455621A1 (en) | Use of (r/s)-(-/+) or (s)-(+)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chromane for the treatment of extrapyramidal movement disorders | |
| DK163172B (da) | Fremgangsmaade til fremstilling af ascorbinsyregranulat indeholdende pvp | |
| AU8447991A (en) | Antineoplastic effect potentiator and antineoplastic agent | |
| IE892654L (en) | Therapeutic nucleosides | |
| WO2026015623A3 (en) | Pharmaceutical formulations comprising dydrogesterone and methods of preparation thereof | |
| WO2006115770A3 (en) | Orally disintegrating pharmaceutical tablet formulations of olanzapine | |
| ZA202400915B (en) | Pharmaceutical composition and use thereof | |
| BE2016C017I2 (cg-RX-API-DMAC7.html) | ||
| IE780921L (en) | 1-acyl-2-hydroxy-1,3-diamino-propanes. | |
| PL379703A1 (pl) | Środek farmaceutyczny jako stała postać dawkowana i sposób jego wytwarzania | |
| MX2025011805A (es) | Analogo y derivado de calcitonina y uso de los mismos |